Integra LifeSciences Holdings Corporation — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2016. The filing was signed July 28, 2016. Results are presented on a continuing-operations basis following the July 1, 2015 distribution of SeaSpine, whose prior-year results are classified as discontinued operations.
Business Context
Integra is a global medical technology company focused on neurosurgery, surgical instruments, extremities orthopedics, wound and soft-tissue repair, regenerative technologies, and related products. Reportable segments are Specialty Surgical Solutions and Orthopedics and Tissue Technologies.
Financial Performance and Position
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Total revenue | $249.3 million | $212.7 million | $486.1 million | $415.2 million |
| Revenue growth | 17.2% | — | 17.1% | — |
| Gross margin | 64.1% | 64.6% | 64.1% | 63.8% |
| Operating income | $22.4 million | $24.3 million | $44.5 million | $45.6 million |
| Operating margin | 9.0% | 11.4% | 9.1% | 11.0% |
| Income from continuing operations | $12.8 million | $12.0 million | $26.2 million | $23.8 million |
| Net income | $12.8 million | $5.0 million | $26.2 million | $13.4 million |
| Diluted EPS from continuing operations | $0.32 | $0.35 | $0.68 | $0.71 |
| Operating cash flow | Not separately provided | Not separately provided | $63.1 million | $71.8 million |
Q2 revenue growth was led by Specialty Surgical Solutions, up 7.8%, and Orthopedics and Tissue Technologies, up 38.2%. Acquired TEI, Salto and Futura products contributed approximately $15.8 million of Q2 revenue and $33.2 million of first-half revenue. Q2 income from continuing operations increased despite lower operating income, primarily reflecting a substantially lower effective tax rate.
As of June 30, 2016, cash and cash equivalents were $86.8 million, compared with $48.1 million at December 31, 2015. Working capital was $344.2 million, compared with $299.4 million at year-end. Total debt included $482.5 million outstanding under the senior credit facility and $227.1 million principal amount of convertible notes due December 15, 2016. Approximately $610.0 million remained available under the credit facility.
Material Changes Versus Prior Period
- Revenue increased $36.6 million in Q2 and $70.9 million year to date, driven by acquisitions, dural repair, regenerative technologies, instruments, and new products.
- Gross margin dollars increased, while Q2 gross margin percentage declined 50 basis points because of acquisition-related inventory step-up charges, additional amortization, and start-up costs for the collagen manufacturing center. First-half gross margin percentage improved 30 basis points.
- Operating expenses increased 21.5% in Q2 and 21.9% year to date. Selling, general and administrative expense rose primarily from expanded sales headcount, TEI-related costs, commissions, and commercial-channel investments. Research and development spending also increased.
- Operating income declined 8.1% in Q2 and 2.4% year to date as expense growth exceeded revenue growth.
- Interest expense increased to $6.6 million in Q2 and $13.0 million year to date, reflecting higher borrowings and borrowing rates. Convertible-debt non-cash interest was $2.1 million in Q2 and $4.2 million year to date.
- The effective tax rate declined to 14.6% in Q2 and 12.6% year to date from 33.3% and 33.6%, respectively. The decrease primarily reflected $1.2 million and $3.0 million of excess tax benefits from early adoption of ASU 2016-09 and releases of uncertain tax positions.
- Operating cash flow decreased $8.7 million year to date, principally because accounts receivable and inventory consumed more cash and prior-year working-capital benefits did not recur.
Outlook, Commentary, Risks and Unusual Items
- Management expected full-year 2016 gross margin of approximately 64.5% to 65.0%, research and development expense of 5.5% to 6.0% of revenue, selling, general and administrative expense of 45.5% to 46.0% of revenue, and an effective tax rate of approximately 20.3%.
- Management anticipated approximately $40.0 million of 2016 capital expenditures, primarily for plant support and automation, the ERP implementation, and orthopedic instrument kits.
- Special charges totaled $16.3 million in Q2 and $30.1 million year to date, including ERP implementation, structural optimization, severance, acquisition-related charges, and non-cash convertible-debt interest. Management stated that some special charges may recur.
- The $227.1 million convertible notes mature in December 2016. Integra intended to refinance, extend, or use available credit capacity, but acknowledged that refinancing depends on operating performance, market conditions, and credit availability.
- TEI remains subject to approximately 50 active product-liability cases involving bovine-derived surgical mesh. BSC manages the litigation; TEI has insurance subject to a $3.0 million retention, and Integra has specified indemnification protections under the TEI merger agreements.
- An FDA warning letter relating to TEI promotional activities remained outstanding. The company had submitted corrective actions and reported no material remediation expenses during the period, but the FDA could require additional actions.
- Integra entered into interest-rate swaps with a total notional amount of $100.0 million effective December 31, 2016, and added another $50.0 million swap on July 12, 2016.
- Foreign currency movements, healthcare-market pressure, regulatory compliance, product liability, acquisition integration, ERP implementation, and reliance on successful commercial investments remain material risks. Management stated that disclosure controls were effective and that no material changes in internal control occurred during the quarter.
Important Facts for Investors to Verify
- Progress on refinancing or otherwise settling the $227.1 million convertible notes due December 2016.
- Whether acquisition-driven revenue growth converts into improved operating leverage as TEI and other acquisitions mature.
- Actual full-year gross margin, SG&A, research and development, tax-rate, and capital-expenditure results versus management’s stated expectations.
- Cash conversion, inventory and receivables growth, and available borrowing capacity under the senior credit facility.
- Developments in the TEI product-liability litigation, insurance coverage, indemnification protection, and FDA remediation.
- ERP implementation costs, structural optimization charges, acquisition-related expenses, and other items excluded or identified as special charges.
- Impact of currency movements, interest-rate changes, and the effectiveness of the company’s hedging arrangements.